Source:http://linkedlifedata.com/resource/pubmed/id/20850972
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
22
|
| pubmed:dateCreated |
2010-10-19
|
| pubmed:abstractText |
The rational design of a novel series of pyrrolidine derivatives as neurokinin-3 receptor antagonists is reported starting from a selective neurokinin-1 receptor antagonist. Typical representatives in this series showed in vivo efficacy after oral administration in a NK3 mediated functional assay. This series of NK3 antagonists shows promise to deliver a novel antipsychotic.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1464-3405
|
| pubmed:author |
pubmed-author:BallardTheresa MTM,
pubmed-author:BissantzCaterinaC,
pubmed-author:HoffmannTorstenT,
pubmed-author:JablonskiPhilippeP,
pubmed-author:KnoflachFredericF,
pubmed-author:KnustHennerH,
pubmed-author:MalherbeParichehrP,
pubmed-author:NettekovenMatthiasM,
pubmed-author:Patiny-AdamAngeliqueA,
pubmed-author:RatniHassenH,
pubmed-author:RiemerClausC,
pubmed-author:SchmittMoniqueM,
pubmed-author:SpoorenWillW
|
| pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6735-8
|
| pubmed:meshHeading | |
| pubmed:year |
2010
|
| pubmed:articleTitle |
Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.
|
| pubmed:affiliation |
F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Preclinical Research, CH-4070 Basel, Switzerland. hasane.ratni@roche.com
|
| pubmed:publicationType |
Journal Article
|